1 Min Read
Oct 24 (Reuters) - Denovo Biopharma:
* Denovo Biopharma receives FDA’s permission to proceed a phase 3 clinical trial with DB102 (enzastaurin) in the first line treatment of high risk DLBCL Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.